Life science companies are working around the clock to develop therapies, treatments and tests to address the COVID-19 pandemic head-on. In support, regulatory bodies around the world have recognized the immediate threat to clinical research and encouraged the decentralization and digitization of trials. For the industry, pivoting to a digital-based approach can help reduce patients’ exposure during a pandemic and provide business continuity for sponsors. By adapting and updating protocols, research becomes more convenient for patients and their loved ones.
Now, more than ever, it’s critical to have a strategy to implement remote engagement at scale to maintain and advance lifesaving clinical research. In this complimentary webinar, our experts will equip you with the essential building blocks needed to ensure your program continues forward in an era where digital avenues will be paramount.
Components of a well-structured decentralized trial include:
- Electronic clinical outcome assessments (eCOA)
- Providing and utilizing devices to capture key endpoints and measurements
- Digitally inclusive study designs and protocols
Integrating these elements can provide patients the opportunity to participate in clinical research during the COVID-19 pandemic from the comfort and safety of their own home.
Each day, the industry’s traditional view of clinical trials is being challenged as biotechnology and pharmaceutical companies transition to flexible, digitally enabled study models. Sponsors are making transformations today and future-proofing against risk and complexities in parallel. Embracing a digital mentality and infrastructure is both inevitable and imperative – this is how trials have and will continue to evolve.